Neuren’s partner has extended US patent protection for trofinetide as a European launch and FDA meeting draw closer.
What lies on the calendar for Neuren Pharmaceuticals (ASX:NEU) after its patent boost?
Neuren’s partner has extended US patent protection for trofinetide as a European launch and FDA meeting draw closer.